PHAR’s Michael S. Broder, MD, MSHS, Eunice Chang, PhD, Sarah N. Gibbs, MPH, and Irina Yermilov, MD, MPH, in collaboration with Bristol-Myers Squibb, conducted a study on real-world treatment patterns of patients with rheumatoid arthritis (RA). The investigators performed a multi-center retrospective medical record review, assessing treatment persistence in adult patients with RA complicated by poor prognostic factors. They found that patients on abatacept, including the subgroup of patients with poor prognostic factors, stayed on treatment longer and had a lower risk of discontinuation due to disease progression than patients on tumor necrosis factor-inhibitors. Their findings were published in the Journal of Health Economics and Outcomes Research and can be read here.